



CERTIFICATE OF MAILING
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED
WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT
POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:
COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450,
ON November 20, 2006

Theresa M. Reward
Signature of Person Mailing this Document

November 20, 2006

DATE

Attorney Docket No. PU60417

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Heerding, et al. 20 November 2006
Serial No.: 10/565,329 Group Art. Unit No.: Not Assigned
Filed: 28 July 2004 Examiner: Unknown
For: INHIBITORS OF AKT ACTIVITY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


FILING OF A SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,

Wayne J. Dustman
Attorney for Applicants
Registration No. 33,870

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5023
Facsimile (610) 270-5090
N:\WJD\AKT\PU60417\Supp IDS Letter.doc



Form PTO-1449 NOV 22 2006		U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. PU60417	SERIAL NO. 10/565,329
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Heerding, et al.		
		FILING DATE 28 July 2004	GROUP Not Assigned	

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
		6,130,333	10/10/2000	Huang, et al.			
		6,211,367	04/03/2001	Cavalla, et al.			
		2005/0153978	07/14/2005	Alberti, et al.			(P33018)
		2005/0197328	07/14/2005	Bailey, et al.			(P33019)
		2004/0034037	02/19/2004	Harbeson, et al.			
		5,958,950	09/28/1999	Padia, et al.			
		5,972,980	10/26/1999	Cornicelli, et al.			
		6,001,866	12/14/1999	Cornicelli, et al.			
		7,041,687	05/09/2006	Binch, et al.			
		6,897,208	05/24/2005	Edwards, et al.			
		2005/182075	08/18/2005	Yuan			
		2003/220365	11/27/2003	Stewart, et al.			
		6,770,666	08/03/2004	Hashimoto, et al.			
1		7,112,600	09/26/2006	Hashimoto, et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes	No
		WO2001/013882	01.03.2001	PCT				
		WO2005/046678	26.05.2005	PCT				
		WO2005/037198	28.04.2005	PCT				
		WO2005/037197	28.04.2005	PCT				
		EP1702919	28.12.2004	PCT				
		WO2002/32896	25.04.2002	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Anderson, et al., J. Org. Chem., 2003, Vol. 68, pp. 9563-9573
	Abraham, Current Opinion of Imm., 1996, Vol. 8, pp. 412-416.
	Ashby, Current Opinion in Lipidology, 1998, Vol. 9, No. 2, pp. 99-102.
	Bolen, et al., Annu. Rev. Immunol., 1997, Vol. 15, pp. 371-404 and table of contents.
	Brodt, et al., Biochemical Pharm., 2000, Vol. 60, pp. 1101-1107.



U.S. Department of Commerce Patent and Trademark Office		ATTY. DOCKET NO. PU60417	SERIAL NO. 10/565,329
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Heerding, et al.	
		FILING DATE 28 July 2004	GROUP Not Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Bruns, et al., Cancer Research, 2000, Vol. 60, pp. 2926-2935.
	Canman, et al., Oncogene, 1998, Vol. 17, pp. 3301-3308.
	Chen, et al., Cancer Research, 1998, Vol. 58, pp. 1965-1971.
	Choi, et al., Cell Transplantation, 2002, Vol. 11, pp. 359-368.
	Forastiere, Seminars in Oncology, 1993, Vol. 20. No. 4, Suppl. 3, pp. 56-60.
	Holmes, et al., J. of the Nat'l Cancer Inst., 1991, Vol. 83, No. 24, pp. 1797-1805.
	Jackson, Int. J. Biochem. Cell Biol., 1997, Vol. 29, No. 7, pp. 935-938.
	Kath, Exp. Opin. Ther. Patents, 2000, Vol. 10, No. 6, pp. 803-818.
	Kearns, et al., Seminars in Oncology, 1995, Vol. 22, No. 3, suppl. 6, pp. 16-23.
	Kerr and Workman, New Molecular Targets for Cancer Chemotherapy, 1993, CRC Press, Cancer Research Campaign Beatson Laboratories, University of Glasgow, UK. Table of Contents, pp.67-79.
	Kelley, et al., J. Med. Chem., 1995, Vol. 38, pp. 4131-4134.
	Kingston, et al., Studies in Organic Chemsitry, 1986, Vol. 26., pp. 219-235.
	Kitada, et al., Antisense Research & Dev., 1994, Vol. 4, pp. 71-79.
	Kumar, The J. of Biol. Chem., 1981, Vol. 256, No. 20, pp. 10435-10441.
	Lackey, et al., Bioorg. & Med. Chem. Letters, 2000, Vol. 10, pp. 223-226.
	Larock, Comprehensive Organic Transformations, Published 1989, Book Cover & Table of Contents.
	Markman, The Yale J. of Biol. & Medicine, 1991, Vol. 64, pp. 583-590.
	Martinez-Lacaci, et al., Int. J. Cancer, 2000, Vol. 88, pp. 44-52.
	Massague, et al., Cancer Surveys, 1996, ol. 27, pp. 41-64.
	McGuire, et al., Annals of Internal Medicine, 1989, Vol. 111, pp. 273-279.
	Mitsunobu, Synthesis, The Use of Diethyl Azadicarboxylate and Triphenylphosphine, 1981, pp. 1-28.
	Oliff, Biochemica et Biophysica Acta, 1999, Vol. 1423, pp. C19-C30.
	Reilly, et al., Cancer Research, 2000, Vol. 60, pp. 3569-3576.
	Rosania, et al., Exp. Opin. Ther. Patents, 2000, Vol. 10, No. 2, pp. 215-230.
	Sanchez, et al., J. Heterocyclic Chem., 1993, Vol. 30, pp. 855-859.
	Schreiber, et al., Science, 1986, Vol. 232, pp. 1250-1253.
	Scharosky, et al., J. Biomed Sci, 2000, Vol. 7, pp. 292-298.